Results 11 to 20 of about 8,545 (210)

Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants

Metabolites, 2023
The nucleoside analog β-D-N4-hydroxycytidine is the active metabolite of the prodrug molnupiravir and is accepted as an efficient drug against COVID-19.
Pankti C Balar, Kishan Patel, Vivek P Chavda   +2 more
exaly   +3 more sources

A Viroimmunologic Model to Characterize the Antiviral Effect of Molnupiravir in Outpatients Infected With SARS-CoV-2: Implication for Treatment Duration. [PDF]

J Infect Dis
Background The antiviral efficacy of molnupiravir against SARS-CoV-2 is controversial. Here, we develop a model integrating viral and immune dynamics to characterize the mechanism of action of molnupiravir in vivo and its impact on viral dynamics during ...
Nguyen BT, Bertrand J, Agyeman AA, Zhang S, Yu LM, Harris V, Little P, Butler CC, Breuer J, Lowe DM, Standing JF, Guedj J, PANORAMIC study group .   +12 more
europepmc   +4 more sources

Molnupiravir inhibits Bourbon virus infection and disease-associated pathology in mice [PDF]

Journal of Virology
Bourbon virus (BRBV) is an emerging tick-borne virus that can cause severe and fatal disease in humans. BRBV is vectored via the Amblyomma americanum tick, which is widely distributed throughout the central, eastern, and southern United States ...
Gayan Bamunuarachchi, Fang R. Zhao, Traci L. Bricker, Kuljeet Seehra, Andrew Karp, Michael S. Diamond, Adrianus C. M. Boon   +6 more
doaj   +2 more sources

Pharmacokinetics and Safety of Single and Multiple Doses of Molnupiravir in Healthy Male Chinese Adults: An Open‐Label, Fixed Sequence, Phase 1 Study

Clinical and Translational Science
Molnupiravir is an orally administered prodrug of β‐D‐N4‐hydroxycytidine (NHC) that is conditionally approved in China for the treatment of mild to moderate COVID‐19 in nonhospitalized adults at high risk of disease progression.
Jixiang Zhu, Danning Zhang, Zhiping Liu, Bei Yan, Yanqiao Zang, Weiwei Zhao, Fang Sun, Brian M. Maas, Mickie H. Cheng, S. Aubrey Stoch, Haiyan Li   +10 more
doaj   +2 more sources

Prevention is better than healing. Clinical and economic implications of oral antiviral agents in COVID-19: a prospective study [PDF]

Italian Journal of Medicine
COVID-19 represents a threat for frailty patients. This study compares molnupiravir and nirmatrelvir for fragile COVID- 19 patients' efficacy, safety, and cost.
Filomena Pietrantonio, Francesco Rosiello, Matteo Ruggeri, Maria Sofia Cattaruzza, Antonio Vinci, Margherita Lordi, Enrica Cipriano   +6 more
doaj   +3 more sources

Computational Analysis of Molnupiravir [PDF]

International Journal of Molecular Sciences, 2022
In this work, we report in-depth computational studies of three plausible tautomeric forms, generated through the migration of two acidic protons of the N4-hydroxylcytosine fragment, of molnupiravir, which is emerging as an efficient drug to treat COVID-19. The DFT calculations were performed to verify the structure of these tautomers, as well as their
Artem Sharov, Tatyana Burkhanova, Tugba Taskın Tok, Maria Babashkina, Damir Safin   +4 more
openaire   +3 more sources

Molnupiravir: coding for catastrophe [PDF]

Nature Structural & Molecular Biology, 2021
Molnupiravir, a wide-spectrum antiviral that is currently in phase 2/3 clinical trials for the treatment of COVID-19, is proposed to inhibit viral replication by a mechanism known as ‘lethal mutagenesis’. Two recently published studies reveal the biochemical and structural bases of how molnupiravir disrupts the fidelity of SARS-CoV-2 genome replication
Brandon, Malone, Elizabeth A, Campbell
openaire   +2 more sources

A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients [PDF]

, 2022
Little is known about SARS-CoV-2 evolution under Molnupiravir and Paxlovid, the only antivirals approved for COVID-19 treatment. By investigating SARS-CoV-2 variability in 8 Molnupiravir-treated, 7 Paxlovid-treated and 5 drug-naive individuals at 4 time ...
Alteri, Claudia, Bernardi, Stefania, Bernaschi, Paola, Burastero, Giulia Jole, Campana, Andrea, Costabile, Valentino, Esperti, Sara, Faltoni, Matteo, Fini, Vanessa, Fontana, Beatrice, Fox, Valeria, Franceschini, Erica, Gallerani, Altea, Granaglia, Annarita, Guaraldi, Giovanni, Meschiari, Marianna, Mussini, Cristina, Perno, Carlo Federico, Russo, Cristina, Scutari, Rossana, Villani, Alberto, Volpi, Sara   +21 more
core   +7 more sources

The use of a new oral antiviral drug molnupiravir in the treatment of COVID-19 from a safety perspective

Качественная клиническая практика, 2022
Molnupiravir is an antiviral drug with a broad spectrum of activity against RNA viruses. The safety of molnupiravir in clinical trials with COVID-19 was analyzed.
A. L. Khokhlov, J. V. Rybachkova
doaj   +1 more source

Interaction between warfarin and molnupiravir in a patient with coronavirus disease 2019 infection

Journal of Family Medicine and Primary Care, 2022
Molnupiravir is a novel antiviral agent for coronavirus disease 2019 (COVID-19) treatment. Warfarin is an oral anticoagulation agent with difficult management due to drug interactions.
Hikari Mizutani, Tetsuro Koide, Takashi Omura, Kumiko Ito   +3 more
doaj   +1 more source